NLS Pharmaceutics AG Financial Flexibility Index
NLS Pharmaceutics AG financial flexibility index. NLS Pharmaceutics AG (NLSP) has a Financial Flexibility Index of -1.43x as of September 2025. Free cash flow of $-2.07 Million (operating CF $-2.07 Million minus capex $0.00) represents -1% of total liabilities ($1.46 Million). See NLSP cash flow after capex ratio to measure how efficiently the company converts operating cash flow to free cash.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Financial Flexibility Index of NLS Pharmaceutics AG (2017–2024)
Financial flexibility index of NLS Pharmaceutics AG from 2017 to 2024. Historical Financial Flexibility Index trend for NLS Pharmaceutics AG across 8 annual periods. Check NLS Pharmaceutics AG cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
NLS Pharmaceutics AG Financial Flexibility Index by Year (2017–2024)
NLS Pharmaceutics AG financial flexibility index by year from 2017 to 2024. Year-by-year free cash flow to debt coverage for NLS Pharmaceutics AG. For the full cash flow conversion analysis, see NLSP cash generation efficiency.
| Year | Flexibility Index | Free Cash Flow (USD) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2024 | -5.16x | $-4.26 Million | $-4.27 Million | $826.76K | ▼ -468.8% |
| 2023 | -0.91x | $-9.68 Million | $-9.68 Million | $10.68 Million | ▲ +60.8% |
| 2022 | -2.31x | $-13.88 Million | $-13.88 Million | $6.00 Million | ▲ +18.8% |
| 2021 | -2.85x | $-14.90 Million | $-14.94 Million | $5.22 Million | ▼ -3887.3% |
| 2020 | -0.07x | $-729.38K | $-729.39K | $10.20 Million | ▼ -226.5% |
| 2019 | -0.02x | $-150.45K | $-190.01K | $6.87 Million | ▲ +92.7% |
| 2018 | -0.30x | $-2.69 Million | $-2.73 Million | $8.96 Million | ▲ +44.6% |
| 2017 | -0.54x | $-5.43 Million | $-5.43 Million | $10.01 Million | — |